John Carter

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Alice P. Chen, Jiuping Ji et al. · Cancer Research · 2011 · 255 citations

Medicine, Oncology, Pharmacology +17

The Neuroplasticity-Associated Arc Gene Is a Direct Transcriptional Target of Early Growth Response (Egr) Transcription Factors

Lin Li, John Carter, Xiaoguang Gao et al. · Molecular and Cellular Biology · 2005 · 234 citations · Full text

Medicine, Neurobiology, Neuroscience +14

Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts

Annamaria Rapisarda, J. Zalek, Melinda G. Hollingshead et al. · Cancer Research · 2004 · 187 citations

Medicine, Oncology, Pharmacology +16

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Annamaria Rapisarda, Melinda G. Hollingshead, Badarch Uranchimeg et al. · Molecular Cancer Therapeutics · 2009 · 172 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Mark C. Genovese, Roy Fleischmann, Daniel E. Furst et al. · Annals of the Rheumatic Diseases · 2014 · 141 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17